MX2007008848A - Metodos y composiciones para el tratamiento de desordenes oculares. - Google Patents

Metodos y composiciones para el tratamiento de desordenes oculares.

Info

Publication number
MX2007008848A
MX2007008848A MX2007008848A MX2007008848A MX2007008848A MX 2007008848 A MX2007008848 A MX 2007008848A MX 2007008848 A MX2007008848 A MX 2007008848A MX 2007008848 A MX2007008848 A MX 2007008848A MX 2007008848 A MX2007008848 A MX 2007008848A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
methods
ocular disorders
disorders
Prior art date
Application number
MX2007008848A
Other languages
English (en)
Inventor
Luis A Dellamary
Arek Tabak
Shiyin Yee
Original Assignee
Targegen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targegen Inc filed Critical Targegen Inc
Publication of MX2007008848A publication Critical patent/MX2007008848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Abstract

La invencion proporciona metodos y composiciones para la entrega de medicamentos lipofilos que son utiles para el tratamiento de varias enfermedades, desordenes, y patologias oftalmologicas, incluyendo el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, edema macular diabetico, cancer, y glaucoma.
MX2007008848A 2005-06-08 2006-06-07 Metodos y composiciones para el tratamiento de desordenes oculares. MX2007008848A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68911105P 2005-06-08 2005-06-08
US76353706P 2006-01-30 2006-01-30
PCT/US2006/022480 WO2006133411A1 (en) 2005-06-08 2006-06-07 Methods and compositions for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MX2007008848A true MX2007008848A (es) 2008-04-16

Family

ID=37498783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008848A MX2007008848A (es) 2005-06-08 2006-06-07 Metodos y composiciones para el tratamiento de desordenes oculares.

Country Status (10)

Country Link
US (2) US20060292203A1 (es)
EP (1) EP1893216A4 (es)
JP (1) JP2008543775A (es)
AR (1) AR054614A1 (es)
AU (1) AU2006254825A1 (es)
BR (1) BRPI0606172A2 (es)
CA (1) CA2611720A1 (es)
MX (1) MX2007008848A (es)
NZ (1) NZ563984A (es)
WO (1) WO2006133411A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20050056227A (ko) * 2002-10-03 2005-06-14 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
MX2007002208A (es) * 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
CN101272685A (zh) * 2005-09-27 2008-09-24 Irm责任有限公司 包含二芳基胺的化合物和组合物以及它们作为c-kit受体调节剂的用途
RU2597364C2 (ru) 2005-11-01 2016-09-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
RS54533B1 (en) * 2007-03-12 2016-06-30 Ym Biosciences Australia Pty Ltd PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
RS58449B1 (sr) 2007-06-13 2019-04-30 Incyte Holdings Corp Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila
AU2008298657A1 (en) * 2007-09-14 2009-03-19 The Scripps Research Institute MPZP: a small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist
BRPI0819175A2 (pt) * 2007-11-05 2015-05-05 Bausch & Lomb Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2723588A1 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated uses
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20110257125A1 (en) * 2008-10-02 2011-10-20 Rolf Schaefer Mucomimetic compositions and uses therefore
US8669241B2 (en) * 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
WO2010076238A1 (en) 2008-12-29 2010-07-08 Fovea Pharmaceuticals Sa Substituted quinazoline compounds
CA2751517A1 (en) 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
SI2586426T1 (sl) 2009-12-03 2015-11-30 Alcon Research Ltd. Suspenzije nanodelcev, ki vsebujejo karboksivinilni polimer
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
EP2426213A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Marker for sunitnib resistance formation
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CU24163B1 (es) 2011-06-28 2016-03-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
CN103242240B (zh) * 2012-02-10 2016-01-06 上海温康化学研发有限公司 一种磺酰胺类化合物的中间体、其盐及其制备方法
EP2858628A1 (en) 2012-06-25 2015-04-15 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing sunitinib
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
AU2014239252B2 (en) 2013-03-14 2017-07-06 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
US10258613B2 (en) 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CA3072847A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
CN106632076B (zh) * 2016-09-20 2019-04-30 中国药科大学 4,6-二苯基嘧啶类化合物、其制备方法和医药用途
WO2020214799A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
JP2024511994A (ja) * 2021-03-18 2024-03-18 ジェニヴィジョン インク． 眼疾患を処置するための方法および組成物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003199A (en) * 1930-05-31 1935-05-28 Johnson Frank James Automatic coal stoker
US2003149A (en) * 1931-05-22 1935-05-28 Autographic Register Co Manifolding
US2003065A (en) * 1931-06-20 1935-05-28 John R Ditmars Composition for coating sheets, fibrous stocks, and the like
US2004102A (en) * 1932-02-24 1935-06-11 Daniel A Dickey Hollow steel propeller construction
US2004138A (en) * 1932-11-30 1935-06-11 Byers A M Co Method of making wrought iron pipe
US2002165A (en) * 1933-07-08 1935-05-21 Charles A Winslow Air cleaner
US2003187A (en) * 1933-10-02 1935-05-28 Frederick H Shaw Automobile radio device
US2003166A (en) * 1933-10-26 1935-05-28 Zancan Ottavio Front drive for motor cars
US2004092A (en) * 1933-12-15 1935-06-11 John L Chaney Device for indicating the temperature of liquids
US2003060A (en) * 1934-04-02 1935-05-28 Ernest L Heckert Thermostatic controlling device
US2201051A (en) * 1938-04-02 1940-05-14 Bsa Tools Ltd Automatic lathe
US2667486A (en) * 1951-05-24 1954-01-26 Research Corp 2,4-diamino pteridine and derivatives
IE38778B1 (en) * 1973-02-02 1978-05-24 Ciba Geigy New 1,2,4-benzotriazine derivatives
AU535258B2 (en) * 1979-08-31 1984-03-08 Ici Australia Limited Benzotriazines
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US5624925A (en) * 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5214059A (en) * 1989-07-03 1993-05-25 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5776502A (en) * 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
MY107955A (en) * 1990-07-27 1996-07-15 Ici Plc Fungicides.
GB9016800D0 (en) * 1990-07-31 1990-09-12 Shell Int Research Tetrahydropyrimidine derivatives
DE4025891A1 (de) * 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5530000A (en) * 1993-12-22 1996-06-25 Ortho Pharmaceutical Corporation Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US6326487B1 (en) * 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
AU1977997A (en) * 1996-02-23 1997-09-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
DE59707681D1 (de) * 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
EP0968284B1 (en) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
JP3734903B2 (ja) * 1996-11-21 2006-01-11 富士写真フイルム株式会社 現像処理方法
JP3720931B2 (ja) * 1996-11-26 2005-11-30 富士写真フイルム株式会社 ハロゲン化銀写真感光材料の処理方法
US5935383A (en) * 1996-12-04 1999-08-10 Kimberly-Clark Worldwide, Inc. Method for improved wet strength paper
DE59807348D1 (de) * 1997-02-05 2003-04-10 Rolic Ag Zug Photovernetzbare Silanderivate
US6070126A (en) * 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
US6635626B1 (en) * 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
EP1193255A4 (en) * 1999-07-01 2002-08-07 Ajinomoto Kk HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6093838A (en) * 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
US6153752A (en) * 2000-01-28 2000-11-28 Creanova, Inc. Process for preparing heterocycles
US20020165244A1 (en) * 2000-01-31 2002-11-07 Yuhong Zhou Mucin synthesis inhibitors
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001064646A2 (en) * 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
US6608048B2 (en) * 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
AU2001244614A1 (en) * 2000-04-04 2001-10-15 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
ATE385498T1 (de) * 2000-08-11 2008-02-15 Boehringer Ingelheim Pharma Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
ATE415163T1 (de) * 2000-11-01 2008-12-15 Merck Patent Gmbh Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ES2271283T3 (es) * 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
EP1453516A2 (de) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030166932A1 (en) * 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US7338959B2 (en) * 2002-03-01 2008-03-04 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
CA2494695C (en) * 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
BR0313397A (pt) * 2002-08-14 2005-06-28 Vertex Pharmaceuticals Incorpo Inibidores de proteina cinase e usos destes
DE10240262A1 (de) * 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen
KR20050056227A (ko) * 2002-10-03 2005-06-14 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20070011458A (ko) * 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
MX2007002208A (es) * 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
US7210697B2 (en) * 2004-12-16 2007-05-01 Tricam International, Inc. Convertible handle
WO2006101977A2 (en) * 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US20070032493A1 (en) * 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
US20070072682A1 (en) * 2005-09-29 2007-03-29 Crawford James T Iii Head to head electronic poker game assembly and method of operation
RU2597364C2 (ru) * 2005-11-01 2016-09-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US20060292203A1 (en) 2006-12-28
AR054614A1 (es) 2007-07-04
EP1893216A1 (en) 2008-03-05
US20110243999A1 (en) 2011-10-06
AU2006254825A1 (en) 2006-12-14
CA2611720A1 (en) 2006-12-14
JP2008543775A (ja) 2008-12-04
WO2006133411A1 (en) 2006-12-14
BRPI0606172A2 (pt) 2009-06-02
NZ563984A (en) 2011-11-25
EP1893216A4 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
MY160052A (en) Alkoxy compounds for disease treatment
CY1118902T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
MX2010000351A (es) Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos.
SG156649A1 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
WO2007022470A3 (en) Methods and compositions for treating neurological disease
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
WO2007046083A3 (en) Compositions for treatment of eye diseases
MX2009011360A (es) Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos.
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
WO2007089673A8 (en) Compositions and methods for treatment of ophthalmic diseases and disorders
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
WO2003006002A8 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
TW200744627A (en) Methods for the treatment of macular degeneration and related eye conditions
TW200744670A (en) Methods for the treatment of macular degeneration and related eye conditions
TW200740825A (en) Cripowellins and synthetic derivatives thereof as medicaments
WO2006110447A3 (en) Pyrimidine derivatives and their use in the treatment of cancer
WO2005097138A3 (en) Combinations comprising oxcarbazepine to treat affective disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal